Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
11:17am, Thursday, 15'th Sep 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years
10:45am, Wednesday, 14'th Sep 2022
These stocks both yield more than three times the S&P 500 average.
Takeda: A Lot To Like
07:28pm, Tuesday, 13'th Sep 2022
Takeda has a stable, reliable core drug portfolio with some new product areas showing promise. Their global reach puts them on par with western pharmaceutical companies, but also presents a headwind f
Takeda: The Current Price Makes No Sense
05:00pm, Thursday, 08'th Sep 2022
Takeda has a dividend yield of 5.26%. It represents only 28% of free cash flow. Takeda is undervalued by nearly 70%.
Takeda: Benefits From A Falling Yen, But Shares Stuck In A Downtrend
11:27am, Wednesday, 07'th Sep 2022
The USD-JPY cross has surged to fresh 24-year highs, up more than 30% YoY. The currency move is a benefit from Takeda Pharma, but the stock has not performed well in 2022 despite boasting a big divide
TAK or ZTS: Which Is the Better Value Stock Right Now?
12:48pm, Monday, 05'th Sep 2022
TAK vs. ZTS: Which Stock Is the Better Value Option?
TAK vs. ZTS: Which Stock Is the Better Value Option?
12:48pm, Friday, 19'th Aug 2022
TAK vs. ZTS: Which Stock Is the Better Value Option?
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
12:47pm, Wednesday, 03'rd Aug 2022
TAK vs. ZTS: Which Stock Is the Better Value Option?
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript
07:38pm, Friday, 29'th Jul 2022
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 2022 Results Conference Call July 28, 2022 6:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andy Plump - Pre
Takeda sees quarterly profit drop 39% after last year's one-time gains
03:09am, Thursday, 28'th Jul 2022
Japan's Takeda Pharmaceutical Co said on Thursday first-quarter profit slumped 39% percent from a year earlier, when earnings had been boosted by the sale of its diabetes drug portfolio.
What's Winning in 2022? 3 Stocks That Are Doing Fine
06:00am, Saturday, 16'th Jul 2022
Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.
Biotech Public Offerings at 10-Year Low
04:56pm, Monday, 11'th Jul 2022
No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerin
Trial Results Set to Make or Break Small-Cap Pharma Stocks
04:15pm, Wednesday, 06'th Jul 2022
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administrati
Takeda, Nintendo among Japanese firms quietly celebrating weak yen
01:36am, Friday, 17'th Jun 2022
Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as phar
Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?
12:02pm, Wednesday, 15'th Jun 2022
Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%.
